Advertisement
Screener

INHIBRX BIOSCIENCES, INC. (INBX) Graph

INBX Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $0.00; Research and development $23.90M; Operating expenses $32.15M; Income tax $3.00K.
  • 2026-03-31: Revenue (m); Research and development $25.22M; Operating expenses $30.93M; Income tax $0.00.
  • 2025-12-31: Revenue $0.00*; Research and development $25.35M*; Operating expenses $30.92M*; Income tax $0.00*.
  • 2025-09-30: Revenue $0.00; Research and development $28.54M; Operating expenses $33.81M; Income tax $0.00.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

INBX revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.License$0.00License Non Affiliate$0.00Revenue$0.00Operating expenses$32.15MOperating income-$32.15MOther income, net-$68.00KResearch & development$23.90MPre-tax income-$36.65MIncome tax$3.00KNet income-$36.65M

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

INBX revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Reportable Segment$0.00Revenue$0.00Operating expenses$32.15MOperating income-$32.15MOther income, net-$68.00KResearch & development$23.90MPre-tax income-$36.65MIncome tax$3.00KNet income-$36.65M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$0.00$23.90M$32.15M$3.00K-$36.65M
2026-03-31(m)$25.22M$30.93M$0.00-$33.44M
2025-12-31$0.00*$25.35M*$30.92M*$0.00*-$32.83M*
2025-09-30$0.00$28.54M$33.81M$0.00-$35.26M
2025-06-30$1.30M$22.27M$28.69M$2.00K-$28.65M
2025-03-31$0.00$36.88M$42.90M$0.00-$43.31M
2024-09-30$0.00$38.89M$46.80M$0.00-$43.86M
2024-06-30$100.00K$67.63M$161.00M$2.00K$1.86B
2024-03-31$0.00$63.85M$73.83M$0.00-$78.71M
2023-09-30$119.00K$38.06M$45.95M$2.00K-$51.79M
2023-06-30$30.00K$34.11M$41.37M$5.00K-$47.05M
2023-03-31(m)(m)(m)(m)-$48.92M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$0.00$49.12M$63.08M$3.00K-$70.09M
2025-06-30$1.30M$59.14M$71.59M$2.00K-$71.97M
2024-06-30$100.00K$131.48M$234.82M$2.00K$1.78B
2023-06-30$47.00K$71.49M$85.15M$5.00K-$95.97M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$1.30M$87.68M$105.40M$2.00K-$107.22M
2024-09-30$100.00K$170.38M$281.62M$2.00K$1.74B
2023-09-30$166.00K$109.55M$131.10M$7.00K-$147.76M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$1.30M$113.03M$136.32M$2.00K-$140.06M
2024-12-31$200.00K$203.74M$331.65M$2.00K$1.69B
2023-12-31$1.80M$191.64M$221.02M$3.00K-$241.36M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Maze Therapeutics, Inc. (MAZE)United States$1.457B-12.40
Taysha Gene Therapies, Inc. (TSHA)United States$1.564B-14.80
Immunocore Holdings plc (IMCR)$1.613B-90.43
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
NOVAVAX INC (NVAX)United States$1.748B-6.26
Replimune Group, Inc. (REPL)United States$1.186B-3.13
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
Vor Biopharma Inc. (VOR)United States$1.091B1.60
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81